Revisión
Molecular mechanisms of steatosis in nonalcoholic fatty liver disease

P. Pettinelli¹, A. M. Obregón² and L. A. Videla³

¹Department of Food Science, Nutrition and Dietetics. Faculty of Pharmacy. University of Concepción. Concepción. Chile.
²School of Nutrition and Dietetics. Faculty of Health Sciences. University of San Sebastián. Concepción. Chile.
³Molecular and Clinical Pharmacology Program. Institute of Biomedical Sciences. Faculty of Medicine. University of Chile. Santiago. Chile.

Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease and is considered the hepatic manifestation of the metabolic syndrome associated with diabetes mellitus type 2. The prevalence of NAFLD in the general population reaches 15-20%. It is also estimated that nonalcoholic steatohepatitis (NASH) affects 3% of the population. NAFLD refers to a wide spectrum of liver damage, which ranges from simple steatosis or intracellular triglyceride accumulation, to inflammation (NASH), fibrosis and cirrhosis. The mechanisms involved in the accumulation of triglycerides in the liver and subsequent hepatocellular damage are multifactorial and are not completely understood. However, metabolic changes such as insulin resistance (IR) are developed, being a common factor in the retention of fatty acids (FA) within the hepatocytes with oxidation and production of free radicals at the mitochondrial level, which are capable of causing lipid peroxidation, cytokine production, and necrosis. In addition, there are alterations in the hepatic bioavailability of long chain n-3 polyunsaturated fatty acids, conditions that alter the expression of a series of transcriptional factors involved in lipolytic and lipogenic processes in the liver. A greater knowledge of the etiopathogenic mechanisms of NAFLD is fundamental for the development of future effective therapeutic strategies. The pathophysiologial fundamentals of liver steatosis are analyzed in this study.

DOI:10.3305/nh.2011.26.3.5119

Key words: Fatty liver. Obesity. PPAR-alfa. SREBP-1c. n-3 polyunsaturated fatty acids.

MECANISMOS MOLECULARES DE LA ESTEATOSIS EN LA PATOLOGÍA DE HÍGADO GRASO NO ALCOHÓLICO

Resumen
La enfermedad de Hígado graso no alcohólico (HNGA) es la causa más importante de enfermedad hepática crónica y es considerado la manifestación hepática del síndrome metabólico asociado a obesidad y diabetes mellitus tipo 2. La prevalencia de la enfermedad de HNGA en la población general alcanza el 15-20%, estimándose además que la esteatohepatitis no-alcohólica (EHNA) afecta al 3%. El HNGA se refiere a un amplio espectro de daño hepático, que va desde esteatosis simple o acumulación intracelular de triacilglicéridos (TAGs), a inflamación (EHNA), fibrosis y cirrosis. Los mecanismos implicados en la acumulación de TAGs a nivel hepático y subsecuente daño hepatocelular son de carácter multifactorial y no se conocen completamente. Sin embargo, es reconocido que existen alteraciones metabólicas, siendo la resistencia a la insulina (RI) un factor común que genera retención de ácidos grasos y TAGs dentro de los hepatocitos, con la producción de radicales libres a nivel mitocondrial capaces de inducir lipoperoxidación, producción de citocinas y necrosis. Además, existen alteraciones en la biodisponibilidad hepática de ácidos grasos poli-insaturados de cadena larga de la serie n-3, condiciones que alterarían la expresión de una serie de factores de transcripción involucrados en el proceso de lipólisis y lipogénesis a nivel hepático. Un mayor conocimiento de los mecanismos etiopatogénicos de la enfermedad de HNGA es fundamental para el desarrollo de estrategias terapéuticas eficaces a futuro. Los fundamentos fisiopatológicos de la esteatosis son analizados a continuación.

DOI:10.3305/nh.2011.26.3.5119

Palabras clave: Hígado graso. Obesidad. PPAR-alfa. SREBP. 1c. Ácidos grasos poli-insaturados n-3.
**Introduction**

Non alcoholic fatty liver disease (NAFLD) has emerged as the most important cause of chronic liver disease related to the increase in incidence of obesity and diabetes mellitus type 2 in the population. There are secondary, less common, causes of NAFLD including the use of different medicines, antiretroviral drugs, and nutritional causes such as rapid weight loss or total parenteral nutrition. NAFLD refers to a wide spectrum of liver damage, which ranges from simple steatosis or intracellular triglyceride accumulation to inflammation (non alcoholic steatohepatitis, NASH) fibrosis and cirrhosis. The characteristics of liver biopsies include steatosis, when it is more than 5% of the liver weight, mixed inflammatory cellular infiltration, degeneration and hepatocyte necrosis, nuclear glycogen, Mallory bodies and fibrosis. Its clinical implications are mainly derived from its occurrence in the population and its potential to progress to cirrhosis and liver failure, steatosis being comparatively benign with a 0-4% risk of developing cirrhosis in a period of one to two decades, in contrast to the 5-8% of patients with NASH that could develop cirrhosis in a period of approximately 5 years.

Liver biopsy is the gold standard for the diagnosis of NAFLD, considering that it is the only method that can distinguish between simple steatosis, NASH and the degree of fibrosis. However, there are many techniques, such as ultrasound, computed tomography, or magnetic resonance, which can confirm the presence of liver steatosis with a high degree of precision. In addition, alcohol consumption is an important factor, which is restricted to less than 20 and 30 g of alcohol per day in women and men, respectively. Furthermore, it is also necessary to rule out other possible causes such as viral diseases, autoimmune responses, hereditary or metabolic factors, drugs, and toxins.

NAFLD is considered the hepatic manifestation of metabolic syndrome, with a prevalence of 15-20% in the general population, whereas that of NASH affects 3% of the population. In patients with diabetes mellitus type 2 the incidence steatosis is close to 50% and it goes up to 76 to 90% in the obese population. NASH is developed in almost 35% of the cases in obese subjects and in all patients who exhibit morbid obesity and diabetes. This means that many patients with NAFLD have multiple components of metabolic syndrome, IR being an important predicting factor of NAFLD and NASH.

An important issue in the management strategy for these patients is the use of diets promoting a decrease in body weight and improve control over blood sugar, insulinemia, dyslipidemia, and cardiovascular risk. There are a variety of diets that have been recommended for the prevention and treatment of all of the components of metabolic syndrome; however, their use in the treatment of NAFLD is still unknown.

---

**Pathophysiology of NAFLD**

The mechanisms associated with the accumulation of TAGs in the liver and the subsequent hepatocellular damage are multifactorial and not fully understood. The first metabolic abnormality that leads to liver steatosis, involving a lipotoxic reaction with a component of oxidative stress, includes nutritional factors and changes in liver lipid metabolism, which is mainly the result of IR.

**Oxidative Stress and Insulin Resistance Associated with Obesity**

Experimental studies indicate that the excess of FAs induces high levels of β-oxidation, with the production of reactive oxygen species (ROS) such as superoxide radical [O₂⁻] and hydrogen peroxide [H₂O₂] at a mitochondrial respiratory chain level, simultaneously with the induction of necrosis. These results suggest that overeating can cause the excess of FAs in the liver, inducing high rates of β-oxidation and ROS production, which is in accordance with changes in the parameters related to oxidative stress observed in the liver of obese patients with steatosis (fig. 1). In fact, relative to the control values, the liver of obese patients presents (i) a decrease in the antioxidant potential (a decreased superoxide dismutase activity and glutathione content), (ii) an increase in pro-oxidant activity (an increased lipid peroxidation, hydroperoxide content, and protein oxidation), and (iii) Kupffer cell activation (enhanced rates of O₂⁻ production and lipid peroxidation). These parameters are associated with decreased plasma antioxidant capacity and increased levels of serum F₂-isopropanes, the products of arachidonic acid peroxidation.

The imbalance of redox status observed in the liver of obese patients represents a nutritional oxidative stress phenomenon, which is caused by excessive and prolonged consumption of metabolic fuels (carbohydrates and lipids) and/or inadequate supply of dietary antioxidants. In conditions of liver oxidative stress, obese patients exhibit two important alterations associated with this redox imbalance, namely, (i) development of IR, shown by the increase in the HOMA index, which exceeds its normal value by 100%, and (ii) substantial decreased of liver content of long-chain polyunsaturated fatty acids n-3 (LCPUFA n-3) (fig. 1). Under these conditions, hyperinsulinemia and hyperglycemia promote the synthesis of FAs from glucose and inhibit β-oxidation of FA, and the excess of FAs is redirected to the formation of TAGs (fig. 2).

IR causes an increase in peripheral lipolysis, leading to enhancement in free fatty acids (FFA) levels in the
liver, which is potentially toxic for the organ. Although IR causes an alteration in the insulin glucoregulatory pathway, the insulin lipogenic effects are maintained, and the hepatocytes protect themselves by transforming, catabolizing, and exporting the excess FFA. These changes appear to play a key role in the appearance of fatty liver by IR, promoting the mobilization of peripheral FA towards the liver.

The retention of FA and TAGs within the hepatocytes that depends on IR and hyperinsulinemia leads to the production of free radicals at a mitochondrial level, capable of inducing lipoperoxidation, cytokine pro-

**Fig. 1.**—Parameters associated with oxidative stress in obese patients with non alcoholic fatty liver disease, expressed as a percentage of the control values. The numbers in parentheses correspond to the specific references cited. Abbreviations: SOD, superoxide dismutase; GSH, reduced glutathione; LP, lipid peroxidation, measured as production of malondialdehyde; HP, hydroperoxide products of the LP; POX, oxidized proteins; $O_2^-$, superoxide radical; CAOX, plasma antioxidant capacity; F2, F2-isoprostane products of arachidonic acid peroxidation; PUFA n-3, polyunsaturated fatty acid n-3 (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]).

**Fig. 2.**—Induction of oxidative stress and its relationship with insulin resistance (IR) and steatosis in non alcoholic fatty liver associated with obesity. Abbreviations: FA, fatty acids; ROS, reactive oxygen species; PUFA n-3, polyunsaturated fatty acids n-3; PPAR-α (γ), peroxisome proliferator-activated receptor-alfa (gamma); SREBP-1c, sterol regulatory element binding protein 1-c.
duction and hepatocyte necrosis, which may trigger NAFLD progression to the more severe state of NASH. Therefore, from a temporary point of view, fatty liver develops when de novo synthesis exceed the oxidation and re-secretion of TAGs. The sources of FAs that potentially may contribute to fatty liver are (i) peripheral lipids stored in the adipose tissue that reach the liver via plasma FFA, considering that in patients with NAFLD lipolysis in adipose tissue is not totally suppressed, (ii) increased de novo lipogenesis (DNL), (iii) alteration in the synthesis or secretion of lipoproteins, and/or; (iv) reduction in FA oxidation.

The effects of hyperglycaemia and hyperinsulinemia on hepatic glycolysis and lipogenesis are mediated by the activation of different transcription factors such as sterol regulatory element binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor γ (PPAR-γ), which transcriptionally activate the expression of a machinery of genes necessary for lipogenesis. In addition, high concentrations of glucose in the liver, independently of insulin levels, activate carbohydrate responsive element-binding protein (ChREBP) up-regulating the transcription of both pyruvate kinase and lipogenic genes.

Alterations in the hepatic bioavailability of long-chain polyunsaturated fatty acids n-3 (LCPUFA n-3), as mediators of the control of metabolic distribution of FAs and glucose in the liver

LCPUFA n-3, mainly EPA (C20:5n3, eicosapentaenoic acid) and DHA (C22:6n3, docosahexaenoic acid) exert their effects by regulating the metabolism of the lipids in the liver through modifications in the gene transcription. This is carried out by means of (i) inhibition of the expression and processing of SREBP-1c (fig. 3) though a reduced trans-activation of the liver receptor X-α (LXR-α), an agonist of SREBP-1c, with the consequent inhibition of the transcription of the lipogenic and glycolitic genes, and (ii) activation of the transcription of genes involved in FA oxidation acting as a ligand of the peroxisome proliferators-activated receptor a (PPAR-α), which directly influences the distribution of the metabolic fuel (fig. 3). Several studies have shown that the liver of patients with NAFLD shows altered LCPUFA n-3 content, reaching 50% decrease in EPA and DHA levels both in steatosis and steatohepatitis, which can cause down-regulation in signal transduction associated with PPAR-α and a decrease in membrane fluidity and in the number of GLUT4 receptors in insulin-dependent tissues, critical factors of IR. Additionally, one of the factors involved with the depletion of these LCPUFA n-3 is a diminution in the activity by delta-5 and delta-6 desaturases, responsible for the biosynthesis of highly unsaturated FAs.

In an animal model, LCPUFA n-3 supplementation was associated with an improvement of liver steatosis and insulin sensitivity, as well as a decrease in the concentration of fasting FFA and TAGs levels. In obese patients with NAFLD, LCPUFA n-3 supplementation for 12 months decreased the degree of steatosis measured by ultrasonography and ECO-Doppler, in comparison with non supplemented patients; however, the LCPUFA n3 levels in liver phospholipids and the presence or absence of IR were not evaluated. Recently, it has been shown that the administration of LCPUFA n3 in obese patients with NAFLD improve IR, as well as reduce the content of hepatic lipids and the serum levels of alanine aminotransferase and TNF-α.

Transcription Factors in NAFLD

The regulation of lipogenesis and hepatic lipoxidation is under the strict control of a network of nuclear
receptors, which regulate the expression of enzymes that participate in the lipid metabolism in a coordinated manner. While healthy subjects in a post-prandial state, DNL increases by 20-30%, in subjects with NAFLD this process is increased in fasting conditions, without an elevation in postprandial states. These observations support the concept of a sustained increase of DNL in the liver of patients with NAFLD.

Regarding hepatic lipogenesis, it has been shown that the transcription factors SREBP-2c, PPAR-γ, and ChREBP play an essential role in the regulation of genes involved with the synthesis of lipids, glycolysis and lipogenesis, respectively. In addition, factor XBP-1 has recently been identified as a possible factor involved with the accumulation of TAGs in the liver of animal models. The participation of these factors as mechanisms involved in liver steatosis in obesity will be analyzed in the following sections.

**SREBP (Sterol Regulatory Element Binding Protein)**

The protein SREBP is represented by SREBP-1a, SREBP-1c and SREBP-2, key factors in the control of various genes involved in the homeostatic regulation of cholesterol and lipid metabolism. SREBP-1a, SREBP-1c are encoded in a single gene through the use of alternative transcription start sites, differing in the terminal amino sequence, whereas SREBP-2 is encoded in a different gene. SREBP-1a is a potent activator of all SREBP-responsive genes that the synthesis of cholesterol, fatty acids, and TAGs. SREBP-2 activates genes involved in cholesterol synthesis, while SREBP-1c increases the transcription of genes involved in FA synthesis (fig. 3).

The distribution pattern of the SREBPs also differs, being SREBP-1c the major (90%) isoform that controls FA synthesis in the liver. The SREBPs are synthesized as inactive precursors attached to the membrane of the endoplasmic reticulum (ER), where they are associated to two membrane proteins, SCAP (activating protein anchored to the SREBP) and Insig-1 (Insulin-induced gene 1) or Insig-2 (Insulin-induced gene 2), the latter being selectively associated to SREBP-1c. In order to be activated, they are transported through vesicles (COP II) to the Golgi apparatus where, through proteolytic processing by SP1 and SP2, they are freed in order to fulfill their function at a nuclear level. In this way, they reach the nucleus and join the sterol response elements (SREs) of multiple genes, activating their transcription.

SREBP-1c is regulated in response to a series of nutritional and hormonal stimulus both by transcriptional and post-transcriptional mechanisms. Multiple lines of research suggest that insulin has a stimulating effect on FA synthesis through an increase in SREBP-1c, even under IR conditions, whose underlying mechanisms have been recently reviewed.

**Activation of the pro-lipogenic factor SREBP-1c in obesity**

Over a decade ago, it was shown that the genetically obese, insulin resistant, and hyperinsulinemic mouse (ob/ob) had elevated hepatic levels of SREBP-1c, together with an increased expression of synthase fatty acid (FAS), acetyl-CoA carboxylase 1 (ACC-1) and PPAR-γ. In relation to transgenic models, knockout SREBP-1c ob/ob mice presented a significant reduction in the hepatic expression of lipogenic genes preventing liver steatosis, and in mice with overexpressed SREBP-1c, an increase in the content of TAGs in the liver as well as an increase in the enzyme mRNA levels involved with FA synthesis are observed, without an increase in the enzymes that controls cholesterol synthesis.

Among the genes that are regulated by SREBP-1c constituting the main regulators of DNL are ACC-1 (located in lipogenic tissues such as adipose tissue and liver), ACC-2 (located in non-lipogenic tissues such as heart, muscle, and skeletal, and to a lesser extent in the liver), and FAS. In the liver, the FAS gene can be transcriptionally activated by a stimulating factor and by LXR ligands, as it has LXR response elements, therefore maintaining the FA synthesis.

The malonil-CoA formed by ACC-1 is used by FAS to synthesize palmitic acid (C16:0), and through successive elongation and desaturation steps it is possible to form oleic acid (C18:1). One study showed that obese patients with NAFLD presented a significant increase of C18:1 (final product of DNL) in hepatic phospholipids when compared to eutrophic subjects without NAFLD, which suggests that under the condition of IR, the DNL is increased. The malonil-CoA made by the ACC-2 in lipid consuming tissues allosterically inhibits carnitine-palmitoyl transferase-I (CPT-I).

HIV patients present lipodystrophy, NAFLD, and steatohepatitis related to of the adverse effects of antiretroviral therapy. One study determined that patients with HIV and IR had higher hepatic expression of both transcription factors compared with non-obese NAFLD patients. Studies in humans have shown that there are many differences between obese and non-obese patients with NAFLD concerning the expression of hepatic genes related to lipid metabolism, regeneration, apoptosis, and detoxification. When the expression of LXR-α, ChREBP, SREBP-1c, ACC-1, and FAS is studied in non-obese patients with NAFLD and control subjects, increases in the expression LXR-α, SREBP-1c, ACC-1 and FAS are shown, as well as a decrease in the expression of ChREBP in the group of eutrophic patients with NAFLD in comparison with controls. These findings suggest that SREBP-1c may be the dominating factor involved in the regulation of the lipid metabolism, activating the expression of lipogenic genes.

Recently, it was shown that the liver of obese patients had higher level of expression of the pro-
lipogenic factor SREBP-1c in comparison with control subjects, with concomitant 107% increase in the expression of FAS, results that are concurrent with the increase in the DNL process observed in obesity. The previously mentioned decrease of the LCPUFA n3 may constitute a mechanism contributing to the increase in the hepatic DNL in obese patients with NAFLD, favoring the proteolytic release of SREBP-1c attached to the ER membrane and its nuclear abundance, and/or altering the composition of membrane phospholipids, which is associated with IR.

Peroxisome proliferator-activated receptor or PPARs

PPARs are proteins of approximately 56 kD that belong to the super family of steroid nuclear receptors. There are three known isoforms of PPAR, namely, α, β, and γ, which are similarly encoded by individual genes. PPARs act by modulating different cellular functions, including adipocyte differentiation, glucose metabolism, FA oxidation, and inhibition of the expression of inflammatory genes. They present different tissue distribution patterns. For example, PPAR-α is mainly expressed in those tissues involved with the metabolism of FA such as liver, heart, and brown adipose tissue. PPAR-β function has been less characterized. It may have a role in the metabolism of FA with a ubiquitous expression pattern, with greater comparative levels in skeletal and cardiac muscles, as well as nervous tissue. PPAR-γ has a restricted expression pattern, with a prominent expression in the white and brown adipose tissues, with lower levels in spleen, intestine, liver, and lymph nodes. Binding of ligands to PPAR induces a conformational change and the receptor dimerizes forming a heterodimer with 9-cis retinoic acid receptor (RXR), which causes its activation. The activated receptor interacts with specific sequences in the DNA or peroxisome proliferator response elements (PPRE), present in the target gene promoter. The initial PPAR activation process involves degradation of a co-repressor complex and recruitment of co-activating complexes, leading to up-regulation of the expression of the target genes.

Several studies have identified a series of ligands for PPARs such as unsaturated fats, oxidized low density lipoproteins (LDL-ox), VLDL, derived metabolites of linoleic acid, and pharmaceuticals such as fibrates and thiazolidinediones (TZD).

Increase of the expression of the pro-lipogenic factor PPAR-γ in obesity

The Pparg gene, located in the chromosome 3p25, with a highly conserved structure in rats and humans, produces 2 proteins, namely, PPAR-γ1 and PPAR-γ2 has 30 additional amino acids in its extreme amino-terminal, allowing a greater capability of stimulating transcription. PPAR-γ plays a fundamental part in the control of genes involved in lipogenic pathways of adipocytes, promoting the uptake of FA and the differentiation of the adipocyte, with the consequent increase in the content of TAGs in the adipocytes and reduction in the delivery of FA to the liver. It also confers sensitization to insulin through the transcriptional activation of the adiponectin gene in adipocytes, up-regulating its expression. PPAR-γ is the molecular target of TZDs, which increase sensibility to insulin by increasing the plasmatic levels of adiponectin in humans. Because of this action, TZDs are used for their anti-diabetic effects on the liver, skeletal muscle, and adipose tissue.

In animal models of obesity, IR, and diabetes mellitus, increased hepatic PPAR-γ mRNA and protein levels have been found as potential mechanisms of steatosis (fig. 2). In some infections, such as the hepatitis B and C viruses, multiple observations suggest that liver steatosis is a common histological characteristic in which an increase in the expression and/or activity of PPAR-γ could contribute to the regulation of lipid synthesis, causing the development of liver steatosis. Recent findings indicate that hepatic PPAR-γ mRNA levels are significantly increased in obese NAFLD patients with either steatosis or NASH, over lean controls, in agreement with data assessing the PPAR-γ2 isoform.

Similar to SREBP-1c factor, PPAR-γ is regulated by insulin in normal conditions, which probably persists under the condition of IR. Furthermore, a factor that may be related to the expression of PPAR-γ is the presence of polymorphisms in the Pparg gene, a condition that causes susceptibility of developing NAFLD through the adiponectin pathway.

PPAR-α

PPAR-α is expressed in high concentrations in liver tissue in rats and humans. It plays a crucial role in controlling the oxidation of FA by modulating the expression of genes that encode enzymes involved in mitochondrial, peroxisomal, and microsomal FA oxidation. It also regulates the expression of proteins involved in FA binding and esterification and export of FA in VLDL.

There are numerous proteins induced by PPAR-α, among them, Acyl-CoA synthetase (ACS), Acyl-CoA oxidase (AOX), and the CPT system, which have PPREs in their promoting region. The CPT system consists of multiple components, namely, (i) CPT-1, an integral transmembrane protein located in the mitochondrial external membrane that catalyzes the transfer of acyl-CoA to carnitine to generate acyl-carnitine, being the limiting enzyme in mitochondrial FA β-oxidation; in addition to having a PPRE region, CPT-1 has
a regulating sequence that responds to LCPUFA,\(^\text{39}\) (ii) carnitine-acylcarnitine translocase (CACT), a transporter located in the mitochondrial internal membrane, and (iii) CPT-2, a membrane protein of the mitochondrial internal membrane facing the matrix that reverses the reaction catalyzed by the CPT-1.\(^\text{35,36}\) Three tissue specific CPT-1 isoforms have been reported, L-CPT-1 that is mainly expressed in the liver, M-CPT-1 expressed in skeletal muscle and other tissues, and B-CPT-1 located in brain, whereas CPT-2 exists as a unique protein.\(^\text{2,3,36}\) Factors such as FAs, insulin, and thyroid hormone regulate L-CPT-1.\(^\text{39}\)

**Inhibition of the lipoxidative factor PPAR-α in obesity**

In hepatocytes, FAs are oxidized to acetyl-CoA by mitochondrial and peroxisomal β-oxidation. Under normal circumstances, peroxisomal β-oxidation is a less important pathway in FA oxidation compared with mitochondrial β-oxidation, however, in conditions of high fat diets and other metabolic alterations, PPAR-α is activated.\(^\text{2,3,36}\) PPAR-α activation causes an increase in FA uptake at a mitochondrial and peroxisomal level.\(^\text{39}\) Several animal and cellular models indicate that the activation of PPAR-α prevents the infiltration of TAGs in the liver under conditions of increased inflow. Animal models of hepatic steatosis have shown a lower expression of this lipoxidative factor and enzymes with its ligand binding domain, hepatic PPAR-α, in NAFLD obese patients.\(^\text{39}\) The discrepancy observed in the hepatic expression of SREBP-1c in these studies could be caused by the fact that the patients did not exhibit the same nutritional status, as those with SREBP-1c up-regulation were morbidly obese,\(^\text{19}\) while those with normal SREBP-1c levels were not.\(^\text{18}\) A relevant finding recently published by our research group is the significant increase in the hepatic SREBP-1c/PPAR-α ratio in obese patients with NAFLD in comparison with the control group.\(^\text{10}\) This implies a metabolic imbalance between the DNL and the oxidation of FAs in favor of the lipogenic process, a central and determining factor of steatosis in the liver of obese patients. In addition, the SREBP-1c/PPAR-α relationship is associated with plasma insulin levels and the HOMA-IR index, pro-lipogenic factors that determine the increase in peripheral lipolysis and the onset of non-esterificated FA flux to the liver.\(^\text{19}\)

The inverse correlation established between the hepatic SREBP-1c/PPAR-α ratio and the content of LCPUFA n3 in the control group and obese patients with NAFLD is of particular interest\(^\text{\textcircled{1}}\) as it supports the fundamental role of LCPUFA n-3 depletion as a mechanism that directs FAs away from oxidation towards triglyceride storage (fig. 3).\(^\text{39}\)

Besides the key regulating action of the hepatic metabolism of lipids, the activation of PPAR-α plays an important role in the control of inflammatory processes, an action that is carried out by the interference in the activation of the transcriptional factors nuclear factor-κB (NF-κB) and activating protein 1 (AP-1).\(^\text{39}\) Recently, obese patients with steatohepatitis showed (i) inverse and significant correlations between NF-κB or AP-1 with levels of PPAR-α mRNA, and (ii) increases of 7.8 times and 15.1 times in the NF-κB/PPAR-α and AP-1/PPAR-α ratios over control values, respectively.\(^\text{39}\) These findings suggest that, in addition to the pro-lipogenic role that hepatic PPAR-α down-regulation implies, it may represent an important factor in the progression of steatosis to the steatohepatitis associated with obesity.

**Conclusions**

In healthy human beings, saturated FAs are the main metabolic fuel of the liver under most circumstances, whereas the contribution of DNL to the hepatic content of TAGs is rather low (1.6-4.7%).\(^\text{5,6,26}\) However, under the conditions of insulin resistance, as occurs in hyperinsulinemic obese patients with NAFLD, fasting DNL is substantially increased, a response that probably involves the induction of enzymes that participate in...
the hepatic DNL process. Although liver DNL is mainly controlled by SREBP-1c signaling, other factors such as LXR-α and/or activation of ChREBP could also play an important role in the induction of SREBP-1c. However, additional studies are required to verify this assertion in morbid obesity in humans.

Based on relevant data obtained in humans, rather than in animal models that often present characteristics not observed in man, it is concluded that the expression of the transcriptional factors that control lipid metabolism is markedly altered in the liver of obese NAFLD patients with steatosis. This alteration in the liver signaling pathways is associated with several metabolic aberrations that take place within the context involving overnutrition, and the appearance of oxidative stress and IR.

Acknowledgements

The authors would like to express their gratitude for the funding given by the National Fund of Scientific and Technological Development (Fondo Nacional de Desarrollo Científico y Tecnológico - FONDECYT Grants 1060105 and 1090020), CONICYT and UCO 0202 Doctoral Scholarships.

References


62. Yeon JE, Choi KM, Baik SH, Kim KO, Lim HI, Park KH, Kim JY, Park JH, Kim JS, Bak YT, Byun KS, Lee CH. Reduced...
expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2004; 19: 799-804.


74. Pettinelli P, Videla LA. Up-Regulation of PPAR-[gamma] mRNA Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic Mechanism to SREBP-1c Induced Endocannabinoid Metab. (Epub ahead of print).


